In favorable-risk prostate cancer, active surveillance is a feasible and safe long-term treatment option, according to a prospective single-arm cohort study of 993 men with favorable- or intermediate-risk prostate cancer.

During the 15-year study, intervention was offered for a prostate-specific antigen (PSA) doubling time of less than 3 years, Gleason score progression, or unequivocal clinical progression. The mean follow-up to first biopsy was 6.4 years. Fifteen percent of subjects died, with 15 deaths from prostate cancer and 2.8% of patients developed metastatic disease.

Over the course of the study, patients who remained untreated and on surveillance are as follows:

• 5 years: 75.7%

• 10 years: 63.5%

• 15 years: 55.0%

Citation: Klotz L, Vesprini D, Sethukavalan P, et al. Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J Clin Oncol. 2015;33(3):272-277. doi: 10.1200/JCO.2014.55.1192.